Literature DB >> 22114021

Perfusion MRI (dynamic susceptibility contrast imaging) with different measurement approaches for the evaluation of blood flow and blood volume in human gliomas.

H Thomsen1, E Steffensen, E-M Larsson.   

Abstract

BACKGROUND: Perfusion magnetic resonance imaging (MRI) is increasingly used in the evaluation of brain tumors. Relative cerebral blood volume (rCBV) is usually obtained by dynamic susceptibility contrast (DSC) MRI using normal appearing white matter as reference region. The emerging perfusion technique arterial spin labelling (ASL) presently provides measurement only of cerebral blood flow (CBF), which has not been widely used in human brain tumor studies.
PURPOSE: To assess if measurement of blood flow is comparable with measurement of blood volume in human biopsy-proven gliomas obtained by DSC-MRI using two different regions for normalization and two different measurement approaches.
MATERIAL AND METHODS: Retrospective study of 61 patients with different types of gliomas examined with DSC perfusion MRI. Regions of interest (ROIs) were placed in tumor portions with maximum perfusion on rCBF and rCBV maps, with contralateral normal appearing white matter and cerebellum as reference regions. Larger ROIs were drawn for histogram analyses. The type and grade of the gliomas were obtained by histopathology. Statistical comparison was made between diffuse astrocytomas, anaplastic astrocytomas, and glioblastomas.
RESULTS: rCBF and rCBV measurements obtained with the maximum perfusion method were correlated when normalized to white matter (r = 0.60) and to the cerebellum (r = 0.49). Histogram analyses of rCBF and rCBV showed that mean and median values as well as skewness and peak position were correlated (0.61 < r < 0.93), whereas for kurtosis and peak height, the correlation coefficient was about 0.3 when comparing rCBF and rCBV values for the same reference region. Neither rCBF nor rCBV quantification provided a statistically significant difference between the three types of gliomas. However, both rCBF and rCBV tended to increase with tumor grade and to be lower in patients who had undergone resection/treatment.
CONCLUSION: rCBF measurements normalized to white matter or cerebellum are comparable with the established rCBV measurements used for the clinical evaluation of cerebral gliomas.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22114021     DOI: 10.1258/ar.2011.110242

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.990


  25 in total

1.  Cerebral Blood Flow Changes in Glioblastoma Patients Undergoing Bevacizumab Treatment Are Seen in Both Tumor and Normal Brain.

Authors:  Jalal B Andre; Seema Nagpal; Daniel S Hippe; Ali C Ravanpay; Heiko Schmiedeskamp; Roland Bammer; Gerald J Palagallo; Lawrence Recht; Greg Zaharchuk
Journal:  Neuroradiol J       Date:  2015-04-28

2.  Glioma grading by dynamic susceptibility contrast perfusion and 11C-methionine positron emission tomography using different regions of interest.

Authors:  Cornelia Brendle; Johann-Martin Hempel; Jens Schittenhelm; Marco Skardelly; Gerald Reischl; Benjamin Bender; Ulrike Ernemann; Christian la Fougère; Uwe Klose
Journal:  Neuroradiology       Date:  2018-02-20       Impact factor: 2.804

Review 3.  Discrimination between Glioma Grades II and III Using Dynamic Susceptibility Perfusion MRI: A Meta-Analysis.

Authors:  Anna F Delgado; Alberto F Delgado
Journal:  AJNR Am J Neuroradiol       Date:  2017-05-18       Impact factor: 3.825

4.  Investigating dynamic susceptibility contrast-enhanced perfusion-weighted magnetic resonance imaging in posterior fossa tumors: differences and similarities with supratentorial tumors.

Authors:  Simona Gaudino; Massimo Benenati; Matia Martucci; Annibale Botto; Amato Infante; Antonio Marrazzo; Antonia Ramaglia; Giammaria Marziali; Pamela Guadalupi; Cesare Colosimo
Journal:  Radiol Med       Date:  2020-01-08       Impact factor: 3.469

5.  Relative percentage signal intensity recovery of perfusion metrics—an efficient tool for differentiating grades of glioma.

Authors:  K A Smitha; A K Gupta; R S Jayasree
Journal:  Br J Radiol       Date:  2015-05-27       Impact factor: 3.039

6.  Repeatability of Standardized and Normalized Relative CBV in Patients with Newly Diagnosed Glioblastoma.

Authors:  M A Prah; S M Stufflebeam; E S Paulson; J Kalpathy-Cramer; E R Gerstner; T T Batchelor; D P Barboriak; B R Rosen; K M Schmainda
Journal:  AJNR Am J Neuroradiol       Date:  2015-06-11       Impact factor: 3.825

7.  Survival analysis in patients with newly diagnosed primary glioblastoma multiforme using pre- and post-treatment peritumoral perfusion imaging parameters.

Authors:  Asim K Bag; Phillip C Cezayirli; Jake J Davenport; Santhosh Gaddikeri; Hassan M Fathallah-Shaykh; Alan Cantor; Xiaosi S Han; Louis B Nabors
Journal:  J Neurooncol       Date:  2014-08-07       Impact factor: 4.130

8.  Prediction of survival in patients affected by glioblastoma: histogram analysis of perfusion MRI.

Authors:  Andrea Romano; Luca Pasquini; Alberto Di Napoli; Francesca Tavanti; Alessandro Boellis; Maria Camilla Rossi Espagnet; Giuseppe Minniti; Alessandro Bozzao
Journal:  J Neurooncol       Date:  2018-05-02       Impact factor: 4.130

Review 9.  The evolving role of neurological imaging in neuro-oncology.

Authors:  E J Fontana; T Benzinger; C Cobbs; J Henson; S J Fouke
Journal:  J Neurooncol       Date:  2014-08-01       Impact factor: 4.130

10.  Comparison of perfusion- and diffusion-weighted imaging parameters in brain tumor studies processed using different software platforms.

Authors:  Mikhail V Milchenko; Dhanashree Rajderkar; Pamela LaMontagne; Parinaz Massoumzadeh; Ronald Bogdasarian; Gordon Schweitzer; Tammie Benzinger; Dan Marcus; Joshua S Shimony; Sarah Jost Fouke
Journal:  Acad Radiol       Date:  2014-08-01       Impact factor: 3.173

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.